Federal Circuit affirms UCB BioPharma win on epilepsy drug patent

A divided federal appeals court on Wednesday upheld the validity of UCB BioPharma’s patent on epilepsy drug Vimpat, dashing the hopes of more than a dozen other drugmakers who sought to make generic versions before the patent expires in March 2022.

https://www.reuters.com/article/patent-ucb/federal-circuit-affirms-ucb-biopharma-win-on-epilepsy-drug-patent-idUSL2N1SU2NB